Marc Tarle, MD
Psychiatry · New City, NYNPI 1992834683
Payments from drug & device makers
Across 1,303 payments — averaging $18.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$3K
- Teva Pharmaceuticals USA, Inc.$2K
- Neurocrine Biosciences, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Lundbeck LLC$1K
- plus $11K from 32 others
What the payments were for
- Food & beverage$24,08199%
- Education$3311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$910
- Auvelity$376
- VRAYLAR$355
- SPRAVATO$291
- INVEGA SUSTENNA$140
- COBENFY$125
- Dayvigo$121
- NEUROSTAR TMS THERAPY$104
How this compares
$24,412 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 48 | $438,350 |
| Austedo XrDeutetrabenazine | 27 | $311,942 |
| Invega SustennaPaliperidone Palmitate | 56 | $162,764 |
| RexultiBrexpiprazole | 88 | $147,838 |
| AustedoDeutetrabenazine | 12 | $134,698 |
| Abilify MaintenaAripiprazole | 35 | $107,106 |
| VraylarCariprazine Hcl | 59 | $99,541 |
| Lurasidone Hcl | 147 | $46,631 |
| TrintellixVortioxetine Hydrobromide | 59 | $41,144 |
| LybalviOlanzapine/Samidorphan Malate | 21 | $36,815 |
| Aripiprazole | 471 | $30,962 |
| Olanzapine | 467 | $28,863 |
| Fluphenazine Hcl | 162 | $25,796 |
| Chlorpromazine Hcl | 26 | $17,173 |
| Clozapine | 151 | $13,259 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $2,451 | $446,64139 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,917 | $438,35048 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,772 | $254,944123 claims |
| Johnson & JohnsonInvega Sustenna | $2,557 | $162,76456 claims |
| AbbVieVraylar | $3,152 | $99,54159 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $640 | $41,14459 claims |
| Alkermes, Inc.Lybalvi | $1,336 | $36,81521 claims |
| Almatica Pharma LLCSertraline Hcl | $79 | $5,485693 claims |
| Eisai Inc.Dayvigo | $524 | $4,53414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in New City
- Elyssa BarronWhite Plains$12.8M
- Mark DibuonoStaten Island$11.9M
- Ronald BrennerHempstead$11.5M
- Anton PorsteinssonRochester$7.6M
- Michael LiebowitzNew York$7.1M
- Leslie CitromePomona$5.7M
- John KaneGlen Oaks$4M
- Inna Yuryev-GolgerBrooklyn$3M
- Subhdeep VirkBuffalo$3M
- Paul EderNew York$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.